| Home Market Dynamics Macro Trends Sector Trends Company Insights AI Investing Strategies Sign Up Login |
Sector: Pharmaceuticals
| Eli Lilly is making significant strides in the pharmaceutical industry, particularly with its innovative product development in obesity and weight-loss drugs, such as retatrutide, Mounjaro, and Zepbound. The demand for these drugs has seen substantial increases, contributing to robust revenue growth and highlighting consumer preference towards effective healthcare solutions. Breakthrough Therapy designations further underscore their commitment to advancing treatment options. The focus on diversification and innovative therapies positions Eli Lilly favorably in a competitive market. |
| The price action of Eli Lilly (LLY) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The trend sentiment at -0.5 is modestly bearish. The market sentiment at 1.1 is very bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next. There is no clear direction for LLY since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 1.2, and the negative at -0.1 on 2026-08-05. The forces of Stock Price Trend (-0.5), and Sector Price Trend (-0.2) will drive down the price. The forces of Price Level Sentiment (0), Market Risk Appetite (0.6), Option Sentiment (0.8), Valuation Sentiment (1.4), and Sentiment towards Fundamentals (4.2) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
Sign up to reveice notifications on Market Movers
| LLY | ||||||||||||||||
| Date | Attention | Price | StdDev | Price Level | RSI | Hourly RSI | Change | 10 Day Trend | Trend Sentiment | Hourly Trend Sentiment | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | 1%(0.1%) | 1168.77 | 2.4% | 46 | 50 | 61 | 4.72% | 0.05% | -0.5 | 1.2 | 2.3% | 1.1 | Wait | 50% | 4.2 | 6.6 |
| 2026-08-04 | 0%(0%) | 1116.11 | 2.65% | 0 | 42 | 43 | -0.45% | -0.5% | -1.9 | -0.3 | 1.1% | 0.5 | Short | 70% | 2.5 | 4 |
| 2026-08-03 | 0%(0%) | 1121.17 | 2.59% | -2 | 43 | 46 | -2.38% | -0.21% | -1.3 | -0.3 | 1.4% | 0.3 | Wait | 50% | 2.2 | -1 |
| 2026-08-02 | 0%(0%) | -1 | -0.3 | 0.5 | 2 | -1 | ||||||||||
| 2026-08-01 | 0%(0%) | -1 | -0.3 | 0.2 | 1.8 | -1 | ||||||||||
| 2026-07-31 | 0%(0%) | 1148.52 | 2.26% | 15 | 43 | 42 | -0.58% | -0.25% | -1 | -0.3 | 2.4% | 0.4 | Short | 55% | 1.2 | -1 |
| 2026-07-30 | 0%(0%) | 1155.27 | 2.17% | 17 | 44 | 12 | -4.58% | -0.13% | -0.6 | -0.8 | 2.4% | 0.6 | Short | 55% | 1.8 | -1 |
| 2026-07-29 | 0%(0%) | 1210.67 | 1.97% | 71 | 49 | 34 | -0.98% | 0.46% | 1 | -0.2 | 0.8% | 1 | Wait | 50% | 2.8 | -1 |
| 2026-07-28 | 0%(0%) | 1222.61 | 1.93% | 85 | 52 | 65 | 2.05% | 0.58% | 1 | 0.3 | 1% | 0.8 | Long | 55% | 2.5 | -1 |
| 2026-07-27 | 0%(0%) | 1197.99 | 2% | 58 | 41 | 45 | 0.16% | 0.11% | 0.6 | 0.1 | 0.5% | 0.6 | Long | 55% | 1.6 | -1 |
| Wait is the preferred trading strategy with 50% chance of being right. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | ||||||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | ||||||||||||||||
| Analysis | ||
| ● Eli Lilly (LLY) – Equity Research Report Tue. Mar 17, 2026 | ||
| 2026-08-05 17:48:16 Eli Lilly is innovating in drug development, including advancements in treatments like a cannabis-derived drug for PTSD. |
| 2026-08-05 17:48:16 The strong performance and growth prospects suggest a positive outlook for Eli Lilly's stock, encouraging investor confidence. |
| 2026-08-05 17:48:16 Significant revenue growth is being driven by Eli Lilly's obesity drugs, reflecting successful product development and market demand. |
| 2026-08-05 17:48:16 Eli Lilly has demonstrated strong performance in earnings, exceeding analysts’ expectations and raising its full-year guidance. |
| 2026-08-05 17:01:29 Eli Lilly has raised its full-year revenue guidance, reflecting confidence in sustained growth and operational success. |
| 2026-08-05 17:01:29 There are trends indicating a resurgence of interest in healthcare stocks, despite previous underperformance in the sector. |
| 2026-08-05 17:01:29 Eli Lilly's stock has shown strong upward momentum in the market, particularly following positive earnings results and outlook adjustments. |
| 2026-08-05 17:01:29 There is a growing demand for Eli Lilly's weight-loss drugs, notably Mounjaro and Zepbound, which are driving up sales and enhancing the company's market position. |
| 2026-08-05 17:01:29 Eli Lilly's recent earnings reports have significantly exceeded market expectations, highlighting solid financial performance and growth. |
| 2026-08-05 15:47:17 Eli Lilly’s raised guidance suggests a favorable outlook for the company and its products in the future. |
| 2026-08-05 15:47:17 The introduction and success of Mounjaro and Zepbound as innovative solutions in the weight-loss market. |
| 2026-08-05 15:47:17 Eli Lilly's substantial revenue growth indicating strong financial health and positive earnings expectations. |
| 2026-08-05 13:47:36 Analysts are optimistic about Eli Lilly's future, especially after the company's earnings exceeded forecasts and guidance was raised. |
| 2026-08-05 13:47:36 Following a successful earnings report, Eli Lilly is expected to see favorable movements in its stock value, reflecting analysts' confidence. |
| 2026-08-05 13:47:36 Eli Lilly is exploring new avenues for growth by addressing the obesity market with oral weight-loss drugs, highlighting potential for product advancement. |
| 2026-08-05 13:47:36 Eli Lilly's strong earnings report is attributed to the increased demand for its GLP-1 medications, indicating robust financial growth. |
| 2026-08-05 11:48:13 Concerns exist regarding Novo Nordisk’s heavy reliance on obesity drug sales, which may impact investor confidence despite strong overall performances. |
| 2026-08-05 11:48:13 Eli Lilly's management has revised its sales outlook upward based on strong performance and market expectations. |
| 2026-08-05 11:48:13 The differing market reactions to Eli Lilly and Novo Nordisk highlight the competitive dynamics within the pharmaceutical industry regarding weight-loss treatments. |
| 2026-08-05 11:48:13 Eli Lilly's earnings surpassed analysts' forecasts, leading to increased stock prices and optimistic sales guidance for the future. |
| 2026-08-05 11:48:13 The growing consumer demand for weight-loss medications, particularly GLP-1 drugs, is driving growth for companies like Eli Lilly and Novo Nordisk. |
| 2026-08-05 09:32:54 The higher-than-expected demand for Lilly's GLP-1 drugs reflects a positive trend in consumer preference towards these products. |
| 2026-08-05 09:32:54 The significant increase in Lilly's revenue, driven by demand for its GLP-1 drug offerings, showcases strong financial performance. |